Edoardo Carboni , Francesco Maria Stalla , Marco Mendolaro , Brayan Montoya Rodriguez , Enrico Morello , Davide Stradella , Alessandro Lavagna , Guido Pagana , Rodolfo Rocca , Marco Daperno
{"title":"Bowel urgency in ulcerative colitis assessed from patients’ reports: Results of a telemonitoring programme","authors":"Edoardo Carboni , Francesco Maria Stalla , Marco Mendolaro , Brayan Montoya Rodriguez , Enrico Morello , Davide Stradella , Alessandro Lavagna , Guido Pagana , Rodolfo Rocca , Marco Daperno","doi":"10.1016/j.dld.2025.03.019","DOIUrl":"10.1016/j.dld.2025.03.019","url":null,"abstract":"<div><h3>Background</h3><div>Bowel urgency is common in ulcerative colitis (UC), but which patients are affected, and how, has not been fully studied.</div></div><div><h3>Objective</h3><div>We explored associations of bowel urgency with the clinical characteristics of unselected outpatients.</div></div><div><h3>Design</h3><div>The study included adults with UC already enrolled in a telemonitoring programme using the IBD Tool platform. Between January 2021 and May 2024, patients repeatedly completed the Simple Clinical Colitis Activity Index (P-SCCAI) and Monitor at Home IBD – Ulcerative Colitis (MIAH-UC) questionnaires, plus other questionnaires. The submission of contemporary P-SCCAI and MIAH-UC scores was an “event” for analysis. The degree of bowel urgency was determined from responses to three P-SCCAI questions.</div></div><div><h3>Results</h3><div>Overall, 277 UC patients submitted 2768 events. No urgency was reported in 1813 events (66 %), while mild urgency in 538 (19 %), moderate urgency in 272 (10 %) and severe urgency in 145 (5 %). Variables positively associated with moderate-severe urgency at multivariate analysis (<em>P</em> < 0.0001) were female sex, age at diagnosis, disease duration, extensive UC, higher disease activity (MIAH-UC score), higher disease-related disability (IBD Disk), and any medical treatment. In 1750 events, disease was in clinical remission (MIAH-UC ≤3.5), but moderate-severe urgency was reported in 67 (3.8 %) of them. At multivariate analysis, variables associated with urgency during UC remission were age at diagnosis, disease duration, IBD Disk score, any treatment, and female sex.</div></div><div><h3>Conclusion</h3><div>Bowel urgency affects UC patients’ lives and is associated with more severe disability, worse quality of life and higher depression scores. Moderate-severe urgency was reported in 1 in 25 events with UC in remission and increased the patients’ disease-related disability.</div></div>","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":"57 6","pages":"Pages 1190-1196"},"PeriodicalIF":4.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143964597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Improving screening participation: The need for socioeconomic considerations and psychological interventions in colorectal cancer programs","authors":"Chaopeng Zheng , Chengfei Du , Jianyu Lv","doi":"10.1016/j.dld.2025.02.005","DOIUrl":"10.1016/j.dld.2025.02.005","url":null,"abstract":"<div><div>This correspondence discusses Silva et al.'s study on colorectal cancer (CRC) screening adherence and preferences, highlighting its contributions to understanding screening education, method choices, and barriers. While acknowledging the study’s insights, we identify critical limitations, including insufficient consideration of socioeconomic disparities in screening access and participation. Lower socioeconomic groups often face barriers such as financial constraints, time limitations, and healthcare mistrust, which may skew adherence outcomes. Additionally, the study overlooks post-screening psychological impacts (e.g., anxiety from false positives) on long-term compliance. We propose integrating socioeconomic analyses, psychological interventions, and technological innovations (e.g., AI-driven tools for personalized reminders and counseling) to enhance screening equity and adherence. Future research should prioritize these dimensions to optimize CRC screening strategies globally.</div></div>","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":"57 6","pages":"Pages 1331-1332"},"PeriodicalIF":4.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143536807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Giuseppe Privitera , Lucia Monastero , Elena Melita , Elisa Schiavoni , Daniele Napolitano , Antonella Barini , Angela Barini , Barbara Tolusso , Lucrezia Laterza , Antonio Gasbarrini , Franco Scaldaferri , Daniela Pugliese , Alessandro Armuzzi , SAFER Study Group
{"title":"Nonmedical switch of anti-TNF-α biosimilars has no major clinical, pharmacokinetic and psychological impact on patients with IBD - the SAFER Study","authors":"Giuseppe Privitera , Lucia Monastero , Elena Melita , Elisa Schiavoni , Daniele Napolitano , Antonella Barini , Angela Barini , Barbara Tolusso , Lucrezia Laterza , Antonio Gasbarrini , Franco Scaldaferri , Daniela Pugliese , Alessandro Armuzzi , SAFER Study Group","doi":"10.1016/j.dld.2025.01.206","DOIUrl":"10.1016/j.dld.2025.01.206","url":null,"abstract":"<div><h3>Background</h3><div>Data on nonmedical switching from one anti-Tumor Necrosis Factor (TNF)-α biosimilar to another in inflammatory bowel disease (IBD) are relatively sparse. We aimed to study the effects of nonmedical switch from infliximab biosimilar CT-P13 to SB2 and from adalimumab biosimilar ABP 501 to SB5.</div></div><div><h3>Methods</h3><div>In this observational study, consecutive IBD patients receiving nonmedical switch were prospectively followed-up for 12 months. The primary outcome was treatment persistence; other outcomes included: secondary effectiveness outcomes, safety, immunogenicity, inflammatory makers levels and psychometric assessments.</div></div><div><h3>Results</h3><div>A total of 119 and 76 patients were enrolled in the SB2 and SB5 cohorts. Persistence on treatment at 12 months was 84.0 % in the SB2 cohort and 78.9 % in the SB5 cohort. No clinically meaningful changes in other secondary effectiveness outcomes were recorded. Rates of 0.38 and 0.63 adverse events of interest per 100 patient-years were observed in the SB2 and SB5 cohorts. The pharmacokinetics and immunogenicity of either drug were unaffected by nonmedical switch; similarly, levels of inflammatory cytokines remained largely unchanged. No changes in psychometric assessments were recorded.</div></div><div><h3>Conclusion</h3><div>Nonmedical switch of infliximab and adalimumab biosimilars does not significantly affect treatment effectiveness, safety and pharmacokinetics, nor does it have major psychological implications for patients.</div></div>","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":"57 6","pages":"Pages 1171-1179"},"PeriodicalIF":4.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143536808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Metabolic dysfunction-associated steatotic liver disease as a predictor of cognitive performance","authors":"Shicheng Zhao, Qinghua Zhang","doi":"10.1016/j.dld.2025.03.001","DOIUrl":"10.1016/j.dld.2025.03.001","url":null,"abstract":"","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":"57 6","pages":"Pages 1355-1356"},"PeriodicalIF":4.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143639569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Does the SCOPE (Sclerosing Cholangitis Outcomes in PEdiatrics) index effectively predict later liver transplantation in children with sclerosing cholangitis?","authors":"Ugo Cucinotta , Valeria Dipasquale , Claire Mayer , Angela Alibrandi , Bénédicte Pigneur , Servane Avril , Chiara Bergamo , Rossella Morello , Frank Rummele , Claudio Romano , Florence Lacaille","doi":"10.1016/j.dld.2025.03.021","DOIUrl":"10.1016/j.dld.2025.03.021","url":null,"abstract":"<div><h3>Background & Aims</h3><div>The SCOPE (Sclerosing Cholangitis Outcomes in Pediatrics) index was developed to provide the first pediatric prognostic score for primary sclerosing cholangitis (PSC), but its efficacy has yet to be confirmed. We aimed to assess its ability to predict liver transplantation (LT) over a 5-year follow-up.</div></div><div><h3>Methods</h3><div>We retrospectively included PSC-diagnosed patients under 18 years of age from two European tertiary-care centers. The SCOPE index was calculated at diagnosis and at 1, 3, and 5 years post-diagnosis. The ability of the SCOPE index to predict LT was assessed using multivariate Cox regression and ROC curve analysis.</div></div><div><h3>Results</h3><div>Sixty patients were included. In transplanted patients, the mean SCOPE index at diagnosis was similar to non-transplanted patients, but significantly higher at 1, 3, and 5 years post-diagnosis (<em>p</em> < 0.001, <em>p</em> = 0.009, <em>p</em> = 0.006, respectively). Patients with overlapping autoimmune hepatitis (AIH) had higher SCOPE at diagnosis (<em>p</em> = 0.005), but this difference diminished over time. The SCOPE index was a significant predictor of LT at various time points (HRs: 1.32 to 3.44) and showed good-to-excellent discriminative power (AUC 0.87 at diagnosis; 0.97 at 1 year).</div></div><div><h3>Conclusions</h3><div>The SCOPE index effectively predicts LT in pediatric PSC, with strong reliability over time. Coexisting AIH may affect score accuracy at diagnosis due to inflammation.</div></div>","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":"57 6","pages":"Pages 1247-1253"},"PeriodicalIF":4.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143981643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Utility of endoscopy in paediatric gastroenterology and hepatology–Review and updates","authors":"Mohana Sathiaseelan , Tassos Grammatikopoulos","doi":"10.1016/j.dld.2025.01.199","DOIUrl":"10.1016/j.dld.2025.01.199","url":null,"abstract":"<div><div>Paediatric endoscopy has been an integral part of the diagnostic evaluation and management of gastroenterology and hepatology diseases in children. This area of clinical medicine has made meteoric advancements since it was first introduced conserving it's traditional roles of gastroscopy and colonoscopy but broadening significantly it's clinical utility and diagnostic accuracy with new and emerging technology. This article aims to explore and review the current utility and emerging applications of diagnostic and therapeutic endoscopy for the practicing paediatric gastroenterologist and hepatologist.</div></div>","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":"57 6","pages":"Pages 1119-1134"},"PeriodicalIF":4.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143536811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Optimization of ustekinumab dosing in Crohn's disease: Addressing variability in treatment strategies and dosing evaluation","authors":"Shuyuan Wang, Lingkang Wu","doi":"10.1016/j.dld.2025.03.005","DOIUrl":"10.1016/j.dld.2025.03.005","url":null,"abstract":"","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":"57 6","pages":"Page 1346"},"PeriodicalIF":4.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143778957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Federica Lepore , Giovanni Cataletti , Alessandro Massari , Daniele Gridavilla , Rosanna Cannatelli , Giovanni Maconi
{"title":"Should we optimize treatment for Crohn's disease patients in clinical remission who do not achieve transmural response?","authors":"Federica Lepore , Giovanni Cataletti , Alessandro Massari , Daniele Gridavilla , Rosanna Cannatelli , Giovanni Maconi","doi":"10.1016/j.dld.2025.04.002","DOIUrl":"10.1016/j.dld.2025.04.002","url":null,"abstract":"","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":"57 6","pages":"Pages 1359-1360"},"PeriodicalIF":4.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143972653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Correlation between serum thyroid hormone level and metabolic steatohepatitis: A retrospective study","authors":"Chun-Yan Yang , Wei Guan , Yan Liu , Peng Zhang","doi":"10.1016/j.dld.2025.03.006","DOIUrl":"10.1016/j.dld.2025.03.006","url":null,"abstract":"<div><h3>Background</h3><div>Metabolic steatohepatitis (MASH) is a common liver disease, and its association with serum thyroid hormone levels is unclear. This study aimed to analyze the association between MASH and serum levels of thyroid hormones in patients with normal thyroid function.</div></div><div><h3>Methods</h3><div>638 non-alcoholic fatty liver disease patients hospitalized in our hospital from March 2021 to March 2024 were retrospectively selected and divided into MASH (<em>n</em> = 262) and non-MASH (<em>n</em> = 376) groups based on the diagnosis made by expert pathologists. The clinical data of the patients were collected, and multivariate logistic regression analysis was utilized to investigate the association between MASH and serum thyroid hormone levels.</div></div><div><h3>Results</h3><div>Serum levels of thyroid-stimulating hormone (TSH) and free triiodothyronine (FT3) in the MASH group were significantly higher compared to the non-MASH group, and serum free thyroxine (FT4) levels were lower than those in non-MASH group. The FT3/FT4 ratio in MASH group was higher than that in non-MASH group (<em>P</em> < 0.05). Logistic regression analysis showed that serum levels of TSH, FT3 and FT4 were independent influencing factors for MASH. The area under receiver operating characteristic (ROC) curve of TSH, FT3, FT4 and FT3/FT4 for predicting the occurrence of MASH were 0.944, 0.973, 0.753 and 0.959, respectively.</div></div><div><h3>Conclusions</h3><div>Elevated serum levels of TSH, FT3, and the FT3/FT4 ratio, along with decreased serum FT4 levels, were independently associated with an increased risk of MASH.</div></div>","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":"57 6","pages":"Pages 1254-1259"},"PeriodicalIF":4.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143987483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}